13D/13G Filings - Versant Venture Capital VII L.P.

Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime
Transaction
Date
Type Company
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev Report View
2024-02-08
6:24 pm
Purchase
2023-12-31 13G RayzeBio, Inc. Common Stock
RYZB
Versant Venture Capital VII L.P. 4,565,015
7.600%
4,565,015increase
(New Position)
Filing
History
2023-03-10
4:13 pm
Sale
2023-03-01 13D Chinook Therapeutics, Inc.
KDNY
Versant Venture Capital VII L.P. 2,105,107
3.200%
-240,000decrease
(-10.23%)
Filing
History
2022-12-28
4:07 pm
Sale
2022-12-22 13D Chinook Therapeutics, Inc.
KDNY
Versant Venture Capital VII L.P. 2,345,107
3.700%
-567,963decrease
(-19.50%)
Filing
History
2022-08-22
4:15 pm
Unchanged
2022-08-12 13D Chinook Therapeutics, Inc.
KDNY
Versant Venture Capital VII L.P. 2,913,070
4.600%
0
(Unchanged)
Filing
History
2022-04-13
4:43 pm
Sale
2022-04-04 13D Chinook Therapeutics, Inc.
KDNY
Versant Venture Capital VII L.P. 2,913,070
5.300%
-709,953decrease
(-19.60%)
Filing
History
2022-01-13
4:30 pm
Sale
2022-01-03 13D Chinook Therapeutics, Inc.
KDNY
Versant Venture Capital VII L.P. 3,623,023
6.700%
-600,000decrease
(-14.21%)
Filing
History
2021-09-07
5:13 pm
Sale
2021-08-27 13D Chinook Therapeutics, Inc.
KDNY
Versant Venture Capital VII L.P. 4,223,023
9.400%
-510,000decrease
(-10.78%)
Filing
History
2020-10-15
5:16 pm
Purchase
2020-10-05 13D Chinook Therapeutics, Inc.
KDNY
Versant Venture Capital VII L.P. 4,733,023
11.200%
4,733,023increase
(New Position)
Filing
History